Intended for healthcare professionals in the Belux only

Slide decks

Ineffective erythropoiesis slide deck

Further information

As of 25th June 2020, luspatercept is indicated for the treatment of:

  • adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy
  • adult patients with transfusion-dependent anaemia associated with β-thalassaemia

Please visit www.Reblozyl.be for further information (restricted access to healthcare professionals)

Treatment and management guidelines

Key professional associations